Back to News
Market Impact: 0.3
Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
Radiopharm Theranostics announced positive interim data from its U.S. Phase 2b imaging trial of 18F-RAD101 in patients with suspected recurrent brain metastases. The results were selected for a late-breaking oral presentation at the 31st Annual Meeting of the Society, providing external visibility for the program and a potentially positive catalyst for RADX.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
RADX0.68
More News
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Fed chairman talks tough on inflation — plus, what's behind Micron's big rally
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Investors Eye AI Payoff in Microsoft, Alphabet Earnings
- Apple brings touch to the Mac, reversing years-old stance on touchscreen laptop
- The 2,000-Nit OLED in Apple’s New MacBook Is a Big Deal